AR051742A1 - Capsulas de lercanidipino - Google Patents

Capsulas de lercanidipino

Info

Publication number
AR051742A1
AR051742A1 ARP050104209A ARP050104209A AR051742A1 AR 051742 A1 AR051742 A1 AR 051742A1 AR P050104209 A ARP050104209 A AR P050104209A AR P050104209 A ARP050104209 A AR P050104209A AR 051742 A1 AR051742 A1 AR 051742A1
Authority
AR
Argentina
Prior art keywords
polyalcoholic
fatty acid
acid ester
ester
lercanidipine
Prior art date
Application number
ARP050104209A
Other languages
English (en)
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of AR051742A1 publication Critical patent/AR051742A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una composicion farmacéutica de liberacion modificada comprende lercanidipino disuelto en una sustancia cérea que comprende un éster polialcoholico de ácidos grasos, encontrándose la disolucion contenida en una cápsula farmacéuticamente aceptable. Preferentemente, el éster polialcoholico de ácidos grasos es un éster del macrogol, un éster del polipropilenglicol, un glicérido de ácidos grasos o una mezcla de dos o más de los mismos. Más preferentemente, el éster polialcoholico de ácidos grasos es una mezcla de mono-, di- y triglicéridos con mono- y diésteres del macrogol. Se ha demostrado que la administracion oral a un paciente de las composiciones farmacéuticas de liberacion modificada produce una concentracion media de lercanidipino en plasma superior a los 0,5 mg/ml durante las 24 horas posteriores a la administracion.
ARP050104209A 2004-10-05 2005-10-05 Capsulas de lercanidipino AR051742A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61591904P 2004-10-05 2004-10-05
US65679205P 2005-02-25 2005-02-25

Publications (1)

Publication Number Publication Date
AR051742A1 true AR051742A1 (es) 2007-02-07

Family

ID=35455723

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104209A AR051742A1 (es) 2004-10-05 2005-10-05 Capsulas de lercanidipino

Country Status (16)

Country Link
US (1) US20060073200A1 (es)
EP (1) EP1807059A1 (es)
JP (1) JP2008515839A (es)
KR (1) KR20070058632A (es)
AR (1) AR051742A1 (es)
AU (1) AU2005291354A1 (es)
BR (1) BRPI0516179A (es)
CA (1) CA2580525A1 (es)
EA (1) EA200700735A1 (es)
IL (1) IL181938A0 (es)
MX (1) MX2007004105A (es)
NO (1) NO20072332L (es)
PE (1) PE20060946A1 (es)
TW (1) TW200616681A (es)
UY (1) UY29150A1 (es)
WO (1) WO2006037650A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
MX370905B (es) 2006-08-31 2020-01-09 Adare Pharmaceuticals Inc Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
HU197201B (en) * 1985-10-01 1989-03-28 Sandoz Ag Process for producing oral pharmaceutical compositions of controlled solubility of the active components
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
WO1999021534A1 (en) * 1997-10-27 1999-05-06 Merck Patent Gmbh Solid state solutions and dispersions of poorly water soluble drugs
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride

Also Published As

Publication number Publication date
BRPI0516179A (pt) 2008-08-26
AU2005291354A1 (en) 2006-04-13
JP2008515839A (ja) 2008-05-15
PE20060946A1 (es) 2006-10-02
KR20070058632A (ko) 2007-06-08
IL181938A0 (en) 2007-07-04
US20060073200A1 (en) 2006-04-06
WO2006037650A1 (en) 2006-04-13
EA200700735A1 (ru) 2007-10-26
TW200616681A (en) 2006-06-01
NO20072332L (no) 2007-05-04
MX2007004105A (es) 2007-06-15
UY29150A1 (es) 2005-11-30
EP1807059A1 (en) 2007-07-18
CA2580525A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
US11207286B2 (en) Self-emulsifying composition of w3 fatty acid
ES2262741T3 (es) Uso de acidos grasos poliinsaturados para la prevencion de accidentes cardiovasculares importantes.
ES2841344T3 (es) Composición autoemulsionante de ácidos grasos omega-3
DK1152755T3 (da) Essentielle fedtsyrer til forebyggelse af cardiovaskulære tilfælde
AR051742A1 (es) Capsulas de lercanidipino
WO2002039983A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
UA102477C2 (en) Capsule composition
JP2012513774A (ja) ニトロ脂肪酸を含有する栄養補助物
NO20014719L (no) Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
RU2011139638A (ru) Сублингвальная фармацевтическая композиция, содержащая нейтральное масло
ATE301989T1 (de) Orale pharmazeutische zusammensetzung mit einem wirkstoff, der bei seiner ersten darmpassage starken wirkungen ausgesetzt werden kann
MX2009009997A (es) Preparacion de la capsula de tamibarotene.
ES2932248T3 (es) Combinaciones sinérgicas antiinflamatorias que comprenden ácido graso omega-3, licopeno de tomate, luteína y ácido carnósico
EP2214653B1 (en) Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
KR20090103000A (ko) 관절염 치료를 위한 약제학적 조성물
ES2243328T7 (es) Preparado farmaceutico que contiene agentes citostaticos y aceptores de electrones para tratar cancer.
ES2666836T3 (es) Formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral
CO4970788A1 (es) Formulaciones orales para drogas hidrofilicas
KR101519887B1 (ko) 고지혈증치료제 및 오메가-3 지방산을 함유하는 복합제제
RU2000108267A (ru) Фармацевтические композиции на основе нестероидных противовоспалительных средств
TH82344A (th) เลอร์คานิไดปีนแคปซูล
TH82344B (th) เลอร์คานิไดปีนแคปซูล
RU2019108285A (ru) Новая улучшенная композиция рацекадотрила
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
AR027286A1 (es) Preparacion farmaceutica estable de oxaliplatina para administracion por via parenteral y procedimiento para preparar dicha preparacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure